tiprankstipranks

Mark Chin Insider Profile

11 Followers
Mark Chin, Director at Iterum Therapeutics, holds 0.00 shares in Harpoon Therapeutics (Ticker: HARP), holds 18.31K shares in Iterum Therapeutics (Ticker: ITRM), holds 0.00 shares in Pyxis Oncology (Ticker: PYXS).
tipranks
Mark Chin

Mark Chin
Iterum Therapeutics (ITRM)
Director

Ranked #88,777 out of 100,202 Corporate Insiders

Profitable Transactions

38%
3 out of 8 Profitable Transactions

Average Return

-26.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$53M
99.94%
0.06%
0.00%
0.00%
A breakdown of Mark Chin's holdings

Insider Roles

Enliven Therapeutics
(ELVN)
Director
Iterum Therapeutics
(ITRM)
Director
Pyxis Oncology
(PYXS)
Former Director
Disc Medicine
(IRON)
Director
Roles that Mark Chin holds in companies

Most Profitable Insider Trade

Stock:
Harpoon Therapeutics
(HARP)
Rating:Informative Sell
Date:Dec 10, 2019 - Dec 10, 2020
Return:+21.80%
The most profitable trade made by Mark Chin

Mark Chin's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Iterum Therapeutics
Jun 15, 2023
Director
Uninformative Buy
17.60K
$32.40K
HARP
Harpoon Therapeutics
Mar 11, 2024
Uninformative Sell
$0.00
Enliven Therapeutics
Jul 28, 2021
Director
Informative Buy
8.00M
$52.67M
Pyxis Oncology
Apr 25, 2022
Former Director
Informative Sell
5.32M
$0.00
Disc Medicine
Director
List of latest transactions for each holding click on a transaction to see Mark Chin's performance on stock

Mark Chin insider profile FAQ

What is the percentage of profitable transactions made by Mark Chin?
The percentage of profitable transactions made by Mark Chin is 38%.
    What is the average return per transaction made by Mark Chin?
    The average return per transaction made by Mark Chin is -26.40%.
      What stocks does Mark Chin hold?
      Mark Chin holds: ITRM, HARP, ELVN, PYXS, IRON stocks.
        What was Mark Chin’s latest transaction?
        Mark Chin latest transaction was an Uninformative Sell of ―.
          What was Mark Chin's most profitable transaction?
          Mark Chin’s most profitable transaction was an Informative Sell of HARP stock on December 10, 2019. The return on the trade was 21.80%.
            What is Mark Chin's role in Iterum Therapeutics?
            Mark Chin's role in Iterum Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.